Compare MOVE & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | KALA |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 16.1M |
| IPO Year | 2021 | 2017 |
| Metric | MOVE | KALA |
|---|---|---|
| Price | $11.61 | $0.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | ★ 2.6M | 941.6K |
| Earning Date | 11-14-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $1,460.71 | N/A |
| Revenue Next Year | $96.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.67 | $0.35 |
| 52 Week High | $54.40 | $20.60 |
| Indicator | MOVE | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 35.36 |
| Support Level | $12.68 | $0.40 |
| Resistance Level | $16.25 | $0.46 |
| Average True Range (ATR) | 3.11 | 0.05 |
| MACD | -0.53 | -0.00 |
| Stochastic Oscillator | 1.15 | 20.40 |
Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.